2-hydroxypropylamine aryl ester derivatives and pharmaceutical use

ABSTRACT

Novel compounds of the general formula ##STR1## wherein Ar represents a substituted or unsubstituted aromatic or heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR 2  COR 1 , --NR 2  CONR 1  R 3 , --NR 2  SO 2  R 1 , --NR 2  SO 2  NR 1  R 3 , or --NR 2  COOR 1  wherein R 1 , R 2  and R 3  may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R 1  is not hydrogen when B is --NR 2  SO 2  R 1  or --NR 2  COOR 1 , or R 1  and R 3  may together with N form a 5 to 7 membered heterocyclic group; and the pharmaceutically acceptable salts thereof. These compounds exhibit β-adrenergic blocking activity and are also useful in the treatment of glaucoma.

This application is a division, of application Ser. No. 06/838,082,filed March 10, 1986, now U.S. Pat. No. 4,810,717 which is a div. ofSer. No. 320,773 filed Nov. 12, 1981, now U.S. Pat. No. 4,582,855.

BACKGROUND OF THE INVENTION

Compounds of the present invention are useful because of their valuablepharmaceutical properties. They exhibit β-adrenergic blocking activityand are also useful in the treatment of glaucoma.

The present invention also relates to the treatment or prophylaxis ofcardiac disorders. More particularly, the invention relates to a novelmethod of treatment or prophylaxis of cardiac disorders which comprisesadministration of β-adrenergic blocking agents and to compounds usefulin such method.

The therapeutic and prophylactic uses of compounds which blocksympathetic nervous stimulation of β-adrenergic receptors in the heart,lungs, vascular system and other organs are well documented. Typically,such compounds are administered therapeutically to patients sufferingfrom ischemic heart disease or myocardial infarction for the purpose ofreducing heart work, i.e., heart rate and contractile force. Reducingheart work reduces oxygen demand, and may also actually increase oxygensupply. Thus reducing heart work can aid in the prevention of furthertissue damage and can relieve angina pectoris.

β-Adrenergic stimulation may also aggravate or cause arrhythmias becauseof increased levels of catecholamines. Thus β-blocking agents may beemployed to reduce the risks of arrhythmias.

Some of the compounds of the present invention selectively blockβ-adrenergic receptors in various organs. β-receptors in the heart aregenerally referred to as β₁ receptors, and those associated withvasodilation and bronchodilation are β₂ receptors. Selective β-blockersare preferred for the treatment of cardiac disorders, because they mayhave less potential to cause hypertension or bronchoconstriction. Anumber of β₁ selective adrenergic blocking agents have been discovered[Smith, L. H., J. Appl. Chem. Biotechnol., 28, 201-202 (1978)]. Mostsuch compounds are structural variations of1-amino-3-aryloxy-2-propanol.

Heretofore, the emphasis in β-blocker research has been to developcompounds which can be administered to cardiac patients over longperiods of time. However, often it is desirable in the critical caresetting to quickly reduce heart work or improve rhythmicity during acardiac crisis, e.g., during or shortly after a myocardial infarction.Conventional β-blocking agents can be employed for such treatment, buttheir duration of action may be much longer than desired by thephysician. A β-blocking agent possessing a long duration of action doesnot allow precise control of heart work or prompt reversal of theβ-blocking effect, which may be required in a critical care setting. Forinstance, if heart output becomes dangerously low, it is desirable toquickly reduce or eliminate β-blocking activity. The lingering activityof available β-blocking agents can be counterproductive and can greatlycomplicate the therapeutic decisions required of the physician duringsuch critical care of cardiac patients.

Accordingly, there is a need for a pharmaceutical preparation and methodof treatment, employing a β-adrenergic blocking agent having a shortduration of action.

Compounds of the present invention are novel β-blocking agents. Thepresence of the ester function in these compounds provides forpredictable metabolism of these compounds to metabolites which areinactive as β-blockers and are highly polar and readily excreted.

Some of the compounds of the present invention are metabolized rapidlyafter infusion into the systemic circulation and, therefore, have ashort duration of β-blocking action. Such compounds are particularlyadvantageous since they allow precise control during treatment ofcertain cardiovascular diseases by intravenous administration of thecompound.

Compounds of the present invention are also useful for the treatment ofglaucoma or lowering of intraocular pressure by topical administrationof the compounds to the eye. Compounds with short duration in thesystemic circulation, but with good stability in ocular fluid, areparticularly useful since they have a low potential for producingsystemic side effects.

Glaucoma is a condition of the eye characterized by increasedintraocular pressure. Untreated, the condition can eventually lead toirreversible retinal damage and blindness. Conventional therapy forglaucoma has involved topical administration of pilocarpine and/orepinephrine, administered to the eye several times daily.

The use of various β-blocking agents to lower intraocular pressure iswell documented. For example, U.S. Pat. No. 4,195,085 to Stone disclosesa method for treatment of glaucoma by the optical administration of aβ-blocking compound, timolol maleate. U.S. Pat. No. 4,127,674 disclosesa method of treating glaucoma with labetalol, a known antagonist of bothalpha and beta adrenergic receptors. However, these methods also possesssignificant drawbacks, in that the absorption of the β-blocking compoundinto the systemic circulation can cause undesirable side effects. Suchside effects result from prolonged β-blocking action on the heart,bronchioles and blood vessels. For example, according to Physicians'Desk Reference, Charles E. Baker, Jr., 35th Edition, 1981, p. 1233,adverse reactions to the topical use of timolol maleate can includebronchospasm and heart failure, as well as cardiac conduction defects.Accordingly, there is a need for a method of treatment for glaucoma orfor lowering intraocular pressure which is relatively free of unwantedsystemic side-effects.

SUMMARY OF THE INVENTION

The present invention relates to compounds of the general formula##STR2## wherein Ar represents a substituted or unsubstituted aromaticgroup or heterocyclic group; W represents alkylene of from 1 to about 10carbon atoms; and B represents --NR₂ COR₁, --NR₂ CONR₁ R₃, --NR₂ SO₂ R₁,NR₂ SO₂ NR₁ R₃, or --NR₂ COOR₁ wherein R₁, R₂ and R₃ may be alike ordifferent and may be hydrogen, alkyl, alkoxyalkyl cycloalkyl, alkenyl,alkynyl, aryl, heteroaryl, or aralkyl, except that R₁ is not hydrogenwhen B is --NR₂ SO₂ R₁ or --NR₂ COOR₁, or R₁ and R₃ may together with Nform a 5 to 7 membered heterocyclic group and the pharmaceuticallyacceptable salts thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds of the formula ##STR3##wherein Ar represents a substituted or unsubstituted aromatic group,including monocyclic, polycylic and heterocyclic ring systems; Wrepresents a straight or branched chain alkylene of from 1 to about 10carbon atoms; and B represents --NR₂ COR₁, --NR₂ CONR₁ R₃, --NR₂ SO₂ R₁,--NR₂ SO₂ NR₁ R₃, or --NR₂ COOR, wherein R₁, R₂ and R₃ may be the sameor different and may be hydrogen, alkyl, of from 1 to about 10 carbonatoms, alkoxyalkyl wherein the alkyl groups may be the same or differentand contain from 1 to about 10 carbon atoms, cycloalkyl of from 3 toabout 8 carbon atoms, alkenyl of from 3 to about 10 carbon atoms,alkynyl of from 3 to about 10 carbon atoms, aryl which includesmonocyclic or polycyclic aromatic or heterocyclic ring systems of from 2to about 10 carbon atoms such as phenyl, thiophenyl, imidazole, oxazole,indole, and the like, aralkyl wherein the alkyl group contains fromabout 1 to about 6 carbon atoms and the aryl group representssubstituted or unsubstituted monocyclic or polycyclic aromatic orheterocyclic ring systems of from 2 to about 10 carbon atoms, such asbenzyl, phenethyl, 3,4-dimethoxyphenethyl,1,1-dimethyl-2-(3-indolyl)-ethyl and the like, except that R₁ is nothydrogen when B is --NR₂ SO₂ R₁ or --NR₂ COOR₁, or R₁ and R₃ maytogether with N form a 5 to 7 membered heterocyclic group, such aspyrrolidine, piperidine, piperazine, morpholine or thiomorpholine.Aromatic (Ar) substituents may include lower alkyl of from 1 to about 10carbon atoms, alkenyl of from 2 to about 10 carbon atoms, alkynyl offrom 2 to about 10 carbon atoms, alkoxy wherein the alkyl group containsfrom 1 to about 10 carbon atoms, halogen, acetamido, amino, nitro,alkylamino of from 1 to about 10 carbon atoms, hydroxy, hydroxyalkyl offrom 1 to about 10 carbon atoms, cyano, arylalkoxy wherein the alkylgroup contains from 1 to about 6 carbon atoms and the aryl grouprepresents substituted or unsubstituted phenyl and groups of the formula##STR4## wherein R₄ is lower alkyl, aryl or aralkyl and A is a directbond, alkylene of from 1 to about 10 carbon atoms or alkenylene of from2 to about 10 carbon atoms. The compounds described herein are notlimited to any particular stereoisomeric configuration. Such compoundsmay be administered as their pharmaceutically acceptable acid additionsalts, e.g., as the hydrochloride, sulfate, phosphate, gluconate,tartrate, etc.

Included in the present invention are compounds of the formula ##STR5##wherein Ar represents an aromatic group which may be unsubstituted orsubstituted with alkyl of from 1 to about 6 carbon atoms, alkenyl offrom 2 to about 6 carbon atoms, alkynyl of from 2 to about 10 carbonatoms, alkoxy wherein the alkyl group contains from 1 to about 6 carbonatoms, halogen, acetamido, amino, nitro, alkylamino of from 1 to about 6carbon atoms, hydroxy, hydroxyalkyl of from 1 to about 6 carbon atoms,cyano or arylalkoxy wherein the alkyl group contains from 1 to about 6carbon atoms and the aryl group is substituted or unsubstituted phenyl;W represents alkylene of from 1 to about 10 carbon atoms; and Brepresents --NR₂ COR₁, --NR₂ CONR₁ R₃, --NR₂ SO₂ R₁, --NR₂ SO₂ NR₁ R₃,or --NR₂ COOR₁ wherein R₁, R₂ and R₃ may be the same or different andrepresent hydrogen, alkyl of from 1 to about 6 carbon atoms, alkoxyalkylwherein the alkyl groups may the same or different and contain from 1 toabout 6 carbon atoms, cycloalkyl of from 3 to about 8 carbon atoms,alkenyl of from 2 to about 6 carbon atoms, alkynyl of from 2 to about 6carbon atoms, aralkyl wherein the alkyl group contains from 1 to about 6carbon atoms and the aryl group represents substituted or unsubstitutedmonocyclic or polycyclic aromatic or heterocyclic ring systems of from 2to about 10 carbon atoms, or a substituted or unsubstituted aromatic orheterocyclic group of from 2 to about 10 carbon atoms wherein thesubstitutent groups may be alkyl of from 1 to about 6 carbon atoms,except that R₁ is not hydrogen when B is --NR₂ SO₂ R₁ or --NR₂ COOR₁, orR₁ and R₃ may together with N form a 5 to 7 membered heterocyclic group;and the pharmaceutically acceptable salts thereof.

The present invention also includes compounds of the formula ##STR6##wherein Ar represents phenyl which is unsubstituted or substituted withalkyl of from 1 to about 6 carbon atoms, alkoxy wherein the alkyl groupcontains from 1 to about 4 carbon atoms, halogen, hydroxy, nitro, amino,phenoxy, or benzyloxy; W represents alkylene of from 1 to about 6 carbonatoms; and B represents --NR₂ COR₁, --NR₂ CONR₁ R₃, --NR₂ SO₂ R₁, --NR₂SO₂ NR₁ R₃, or NR₂ COOR₁, wherein R₁, R₂ and R₃ may be the same ordifferent and represent hydrogen, alkyl of from 1 to about 6 carbonatoms, alkoxyalkyl wherein the alkyl groups may be the same or differentand contain from 1 to about 6 carbon atoms, cycloalkyl of from 3 toabout 8 carbon atoms, a substituted or unsubstituted aryl group of from5 to about 6 carbon atoms, or a 5 to 7 membered heterocyclic group,except that R₁ is not hydrogen when B is --NR₂ SO₂ R₁ or --NR₂ COOR₁, orR₁ and R₃ may together with N form a 5 to 7 membered heterocyclic group;and the pharmaceutically acceptable salts thereof.

Additionally the present invention includes compounds of the formula##STR7## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, hydroxyalkyl of from 1 to about 6carbon atoms, nitro, amino, alkyl of from 1 to about 6 carbon atoms,phenoxy benzyloxy, or alkoxy wherein the alkyl group contains from 1 toabout 4 carbon atoms; W represents alkylene of from 1 to about 6 carbonatoms; and B represents --NR₂ COR₁, --NR₂ CONR₁ R₃, --NR₂ SO₂ R₁, --NR₂SO₂ NR₁ R₃, or --NR₂ COOR₁ wherein R₁, R₂, and R₃ may be the same ordifferent and represent hydrogen, alkyl of from 1 to about 6 carbonatoms, alkoxyalkyl wherein the alkyl groups may be the same or differentand contain from 1 to about 6 carbon atoms, cycloalkyl of from 3 toabout 8 carbon atoms, phenyl, benzyl, or a 5 to 7 membered heterocyclicgroup, except that R₁ is not hydrogen when B is --NR₂ SO₂ R₁ or --NR₂COOR₁, or R₁ and R₃ may together with N form a 5 to 7 memberedheterocyclic group; and the pharmaceutically acceptable salts thereof.

Preferred compounds of the present invention are compounds of theformula ##STR8## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, hydroxyalkyl of from 1 to about 6carbon atoms, nitro, amino, benzyloxy, phenoxy, alkyl containing from 1to about 6 carbon atoms, or alkoxy wherein the alkyl group contains from1 to about 6 carbon atoms; W represents ethylene, 1-methylethylene, or1,1-dimethylethylene, and Y is --COR₁, --CONR₁ R₃, --SO₂ NR₁ R₃, or--COOR₁, wherein R₁ and R₃ may be the same or different and may behydrogen, alkyl containing from 1 to about 6 carbon atoms, alkoxyalkylwherein the alkyl groups may be the same or different and contain from 1to about 6 carbon atoms, substituted or unsubstituted phenyl,substituted or unsubstituted heterocyclic group of from 2 to about 10carbon atoms, aralkyl wherein the alkyl group contains from 1 to about 6carbon atoms and the aryl group represents substituted or unsubstitutedphenyl, or a heterocyclic group of from 2 to about 10 carbon atoms,except that R₁ is not hydrogen when Y is --SO₂ R₁ or COOR₁, or R₁ and R₃may together with N form a 5 to 7 membered heterocyclic group; and thepharmaceutically acceptable salts thereof.

Particularly preferred compounds are compounds of the following formulae##STR9## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, nitro, amino, alkyl of from 1 toabout 4 carbon atoms, or benzyloxy; W represents alkylene of from 1 toabout 6 carbon atoms; and R₁ represents alkyl of from 1 to about 6carbon atoms, alkoxyalkyl wherein the alkyl groups may the same ordifferent and contain from 1 to about 4 carbon atoms, cycloalkyl of from3 to about 8 carbon atoms, phenyl, benzyl, or a 5 to 7 memberedheterocyclic group; and the pharmaceutically acceptable salts thereof.##STR10## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, nitro, amino, alkyl of from 1 toabout 4 carbon atoms, or benzyloxy; W represents alkylene of from 1 toabout 6 carbon atoms; and R₁ and R₃ may be the same or different andrepresent hydrogen, alkyl of from 1 to about 6 carbon atoms, alkoxyalkylwherein the alkyl groups may be the same or different and contain from 1to about 4 carbon atoms, cycloalkyl of from 3 to about 8 carbon atoms,phenyl, or benzyl, or R₁ and R₃ may together with N form a 5 to 7membered heterocyclic group; and the pharmaceutically acceptable saltsthereof. ##STR11## wherein X₁, X₂ and X₃ may be the same or differentand represent hydrogen, halogen, hydroxy, nitro, amino, alkyl of from 1to about 4 carbon atoms, or benzyloxy; W represents alkylene of from 1to about 6 carbon atoms; and R₁ represents alkyl of from 1 to about 6carbon atoms, alkoxyalkyl wherein the alkyl groups may be the same ordifferent and contain from 1 to about 4 carbon atoms, cycloalkyl of from3 to about 8 carbon atoms, phenyl, benzyl, or a 5 to 7 memberedheterocyclic group; and the pharmaceutically acceptable salts thereof.##STR12## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, nitro, amino, alkyl of from 1 toabout 4 carbon atoms, or benzyloxy; W represents alkylene of from 1 toabout 6 carbon atoms; and R₁ and R₃ may be the same or different andrepresent hydrogen, alkyl of from 1 to about 6 carbon atoms, alkoxyalkylwherein the alkyl groups may be the same or different and contain from 1to about 4 carbon atoms, cycloalkyl of from 3 to about 8 carbon atoms,phenyl, benzyl, or R₁ and R₃ may together with N form a 5 to 7 memberedheterocyclic group; and the pharmaceutically acceptable salts thereof.##STR13## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, nitro, amino, alkyl of from 1 toabout 4 carbon atoms, or benzyloxy; W represents alkylene of from 1 toabout 6 carbon atoms; and R₁ represents alkyl of from 1 to about 6carbon atoms, alkoxyalkyl wherein the alkyl groups may be the same ordifferent and contain from 1 to about 4 carbon atoms, and thepharmaceutically acceptable salts thereof.

Compounds of the present invention exist as two sterioisomers due to thepresence of an asymmetric carbon atom. The present invention includeseither stereoisomeric form as well as racemic mixtures. For compounds inwhich R₁, R₂ or R₃ represent alkenyl, both cis and trans isomers arewithin the scope of the invention. For compounds in which Ar is asubstituted aromatic ring, the substituents may be in the ortho, meta orpara positions to the propoxy carbonyl side-chain.

The compounds described herein may be prepared by any availableprocedure. Compounds prepared as the acid addition salts may beconverted to the free base by reaction with an appropriate base such assodium carbonate or sodium bicarbonate. The compounds are advantageouslyprepared by one of the following methods:

(1) As shown in Scheme I, an appropriate acyl chloride is reacted withglycidol in the presence of a base such as pyridine. The resultingproduct is then reacted with an appropriate amine in the presence ofdimethylformamide: ##STR14## where Ar, W and B are defined ashereinbefore. (2) As shown in Scheme II, an appropriate amine is reactedwith glycidol. The resulting amino-diol is reacted with an acylchloride. ##STR15## wherein Ar, W, and B are defined as hereinbefore.

Alternatively, as shown in Scheme III, the amino-diol is reacted withp-methoxybenzyloxycarbonyl azide in the presence of sodium bicarbonateand dioxane to protect the amine group. The resulting compound isreacted with an appropriate acyl chloride and the protecting group isremoved by reaction with a suitable acid. ##STR16## wherein Ar, W and Bare defined as hereinbefore.

The acyl chlorides used as starting materials in the above reactionschemes are generally commercially available compounds or may beprepared by methods known in the art.

The amines, H₂ N-W-B, wherein W and B are defined as hereinbefore, maybe prepared by the following methods:

(a) For amidoalkylamines (B=NR₂ COR₁):

    H.sub.2 N-W-NHR.sub.2 +R.sub.1 COOC.sub.2 H.sub.5 →H.sub.2 N-W-NR.sub.2 COR.sub.1

wherein W, R₂ and R₁ are defined as hereinbefore.

(b) For alkoxycarbonylaminoalkyl amines (B=NR₂ COOR₁), either of twomethods were used. ##STR17## wherein W, R₂ and R₁ are defined ashereinbefore.

(c) For ureidoalkylamines (B=NR₂ CONR₁ R₃) any of four methods wereused:

    H.sub.2 N-W-NHR.sub.2 +R.sub.3 N═C═O→H.sub.2 N-W-NR.sub.2 CONHR.sub.3                                               (1)

wherein W, R₂ and R₃ are defined as hereinbefore. ##STR18## wherein W,R₁, R₂ and R₃ are defined as hereinbefore. ##STR19## wherein W, R₂ andR₃ are defined as hereinbefore.

    H.sub.2 N-W-NHR.sub.2 +H.sub.2 NCONH.sub.2 →H.sub.2 N-W-NR.sub.2 CONH.sub.2                                                (4)

wherein W and R₂ are defined as hereinbefore.

(d) For sulfonamidoalkylamines (B=NR₂ SO₂ R₃):

    H.sub.2 N-W-NHR.sub.2 +R.sub.3 SO.sub.2 Cl→H.sub.2 N-W-NR.sub.2 SO.sub.2 R.sub.3

wherein W, R₂ and R₃ are defined as hereinbefore.

(e) For sulfamidoalkylamines (B=NR₂ SO₂ NR₁ R₃), either of two methodswere used: ##STR20## wherein W, R₁, R₂ and R₃ are defined ashereinbefore.

The preparation of some of the starting materials is described incopending U.S. application Ser. No. 211,341 now U.S. Pat. No. 4,405,642which is hereby incorporated by reference.

When used for the treatment of cardiac disorders, compounds of thisinvention are advantageously administered orally or parenterally, e.g.,by intravenous injection or intravenous infusion. Formulations forintravenous injection preferably include the active compound as asoluble acid addition salt in a properly buffered isotonic solution.

The dosage administered to a patient and the duration of infusion willdepend upon the patient's needs and the particular compounds employed.For short periods of infusion, e.g., less than about three hours, theduration of effect is thought to be determined by both metabolic effectsand distribution phenomena. For relatively long periods of infusion,e.g., greater than about three hours, the duration of effect is thoughtto depend largely on metabolic effects. Accordingly, although thepresent methods and compounds are generally useful for short-terminfusion therapy, certain compounds are preferred for longer durationsof infusion. The compounds have been found to be generally non-toxicwithin conventional dosage ranges. Dosages of about 0.0001 to about 100mg. per kg. of body weight per hour are generally employed, withpreferred dosages ranging from about 0.01 to about 10 mg. per kg. ofbody weight per hour.

When used for the treatment of glaucoma, the compounds of this inventionare advantageously administered topically to the eye in the form of asolution, ointment or solid insert such as is described in U.S. Pat. No.4,195,085. Formulations may contain the active compound, preferably inthe form of a soluble acid addition salt, in amounts ranging from about0.01 to about 10% by weight, preferably from about 0.5 to about 5% bywt. Unit dosages of the active compound can range from about 0.001 toabout 5.0 mg., preferably from about 0.05 to about 2.0 mg. The dosageadministered to a patient will depend upon the patient's needs and theparticular compounds employed.

Carriers used in the preparations of the present invention arepreferably non-toxic pharmaceutical organic or inorganic compositionssuch as water; mixtures of water and water-miscible solvents, such aslower alcohols; mineral oils; petroleum jellies; ethyl cellulose;polyvinylpyrrolidone and other conventional carriers. The pharmaceuticalpreparations may also contain additional components such as emulsifying,preserving, wetting and sterilizing agents. These include polyethyleneglycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and10,000, bacteriocidal components such as quaternary ammonium compounds,phenylmercuric salts known to have cold sterilizing properties and whichare non-injurious in use, thimerosal, methyl and propyl paraben, benzylalcohol, phenyl ethanol, buffering ingredients such as sodium chloride,sodium borate, sodium acetates, gluconate buffers, and otherconventional ingredients such as sorbitan monolaurate, triethanolamine,oleate, polyoxyethylene sorbitan monopalmitylate, dioctyl sodiumsulfosuccinate, monothioglycerol, thiosorbitol, ethylenediaminetetracetic acid, and the like. Additionally, suitable ophthalmicvehicles can be used as carrier media for the present purpose, includingconventional phosphate buffer vehicle systems, isotonic boric acidvehicles, isotonic sodium chloride vehicles, isotonic sodium boratevehicles and the like.

The method of treatment of this invention advantageously involves thetopical administration of eye drops containing the active compound.Formulations for eye drops preferably include the active compound as asoluble acid addition salt in a properly buffered, sterile, aqueousisotonic solution.

The compounds of the present invention are ester group-containing betablockers that have a selective, localized, β-blocking effect in the eyeafter topical administration. Such compounds are thought to be rapidlymetabolized by plasma and/or liver esterases into inactive by-products,upon entering the systemic circulation. It has been discovered thatthese same compounds are relatively stable in ocular fluids, i.e.,lacrimal fluids and aqueous humor. Consequently, such compounds areuseful for the treatment of glaucoma or for lowering intraocularpressure since they remain stable when topically applied to the eye butrapidly metabolize when subsequently abosrbed into the systemiccirculation.

Some of the compounds break down in the aqueous humor more rapidly thanothers. Such compounds may advantageously be employed when only atemporary reduction in intraocular pressure is desired, say fordiagnostic procedures. Longer-acting compounds are generally used foreffecting longer-term reductions in intraocular pressure, such as isdesired when treating chronic glaucoma. Thus, the method of the presentinvention provides a very useful therapeutic alternative for thetreatment of glaucoma or for lowering intraocular pressure.

The rate of hydrolysis of the ester function of compounds of the presentinvention is influenced by the type of amine substituent. By varying theamine substituent it is possible to vary the length of duration of thecompound in the body. The presence of the amine substituent also makesthe compounds less lipophilic. Compounds that are less lipophilic have areduced potential to cause central nervous system effects since there isless potential for CNS penetration.

The in vitro studies hereinafter described indicate that the compoundsused in the method of the present invention will undergo different ratesof enzymatic hydrolysis depending on their location within the body (seeTable III). For example, the compound of Example VII is completelyhydrolyzed within 60 minutes in both dog blood and liver homogenatewhile only 31% hydrolyzed after one hour in aqueous humor, and only 54%hydrolyzed after two hours. The compound of Example II is less stable inaqueous humor, hydrolyzing 42% after one hour, 68% after two hours.

The beta adrenergic receptor blocking activity of several compounds ofthe present invention has been demonstrated in vitro (Table I) and invivo (Table II).

BETA BLOCKING ACTIVITY IN VITRO

Several of the compounds of the present invention were tested forβ-blocking activity in vitro using guinea pig right atria and guinea pigtracheal strips mounted in a tissue bath containing oxygenated (95% O₂-5% CO₂) Krebs physiological salt solution at 37° C. Eash tissue wassuspended between a fixed glass rod and a Statham Universal Transducerconnected to a Beckman recorder. Atria were allowed to beatspontaneously under a loading tension of approximately 0.5 gm. Intrinsicdepressant or stimulant activity was determined for each compound byprogressively increasing concentrations in the tissue baths at 60-minuteintervals. Tissues were not washed between increments. The maximumconcentration showing little or no cardiodepressant activity was chosenfor blockade experiments. Changes in rate in response to isoproterenol,a standard β-receptor agonist, were measured in the absence and presenceof test compounds. Spiral strips of guinea pig trachea were suspendedunder 5 gm resting tension and incubated with phentolamine, tropoloneand cocaine. Active tension was generated by addition of carbachol(3.0×10⁻⁷ M) and decreases in tension in response to isoproterenol werequantitated. Cumulative concentration-response curves were produced withisoproterenol both before and after 60-minute incubation of testcompounds with atria and trachea. Compounds with β-blocking activityshifted concentration-response curves to the right. The blocking potencyof test compounds was estimated by computing pA₂ values (-log K₈) by themethod of Furchgott, the Pharmacological Differentiation of AdrenergicReceptors, Ann. N.Y. Acad. Sci., 139: 553-570 (1967). Comparison ofblockade of right atrial and tracheal responses to isoproterenol permitsassessment of cardioselectivity of test compounds; i.e., cardioselectivecompounds are relatively more effective in blocking atrial rate thantracheal force response to isoproterenol. The degree ofcardioselectivity was estimated from the ratio, K_(B) trachea/K_(B)atria (10.sup.(pA 2^(atria-pA) 2^(trachea))). A ratio greater than oneindicates cardioselectivity. Test drugs were dissolved in distilledwater and added to the bath (30 ml) in a volume of 10 or 100 μl. Theresults of the in vitro tests are contained in Table I. All of the testcompounds are active β-blockers.

                  TABLE I                                                         ______________________________________                                        Beta-Blocking Activity In Vitro                                               Compound of                                                                             PA.sub.2       Cardioselectivity                                    Example   Rt. Atria                                                                              Trachea   K.sub.B (Trachea)/K.sub.B (Atria)                ______________________________________                                        I         6.1                                                                 II        8.5      8.2       2                                                III       <6.3                                                                IV        7.5      8.0       -3                                               V         6.8      8.1       -18                                              VI        7.7      7.2       -3                                               VII       7.4      8.1       -5                                               VIII      7.0      6.9       0                                                IX        7.1      7.1       0                                                X         7.7      7.9       -2                                               XI        6.5      8.1       -39                                              XII       7.1      6.4       5                                                XIII      <6.0                                                                XXXI      7.7      7.7       0                                                XXXII     7.4      7.5       0                                                XXXIII    8.3                                                                 XXXIV     7.9                                                                 XXXV      8.2      8.6       -3                                               XXXVI     8.1      8.4       -2                                               XXXVI     8.2      8.4       -1                                               XXXVIII   9.0      8.8       1                                                Propanolol                                                                              8.7      8.9       -1                                               ______________________________________                                    

DURATION AND POTENCY OF BETA-BLOCKING ACTION IN VIVO

The duration of β-blockade was determined in vivo usingpentobarbital-anesthetized dogs instrumented for measurement of heartrate using a Beckman cardiotachometer triggered electronically by aphasic aortic blood pressure signal. Both vagus nerves were severed inthe cervical region and the animals were mechanically ventilated. Theexperimental design used employed a 3-hour infusion of test compound.Bolus doses of isoproterenol (0.5 μg/kg) were used to assess the degreeof β-blockade and recovery from β-blockade after determination of theinfusion. The doses were spaced at 10-minute intervals and were givenbefore, during and following the infusion of test compounds. Theinfusion rate was adjusted so that at the end of the 3-hour infusionperiod the degree of isoproterenol inhibition averaged about 50% ofcontrol. Following termination of blocker infusion, percent recoveryfrom β-blockade was computed and the time associated with 80% recoveryestimated. The results are contained in Table II.

                  TABLE II                                                        ______________________________________                                        β-Blocking Activity In Vivo                                              Compound of                                                                            Potency      Recovery Time (min)                                     Example  (mg/kg/180 min)                                                                            % I.sup.a                                                                             50%   80%    N.sup.b                            ______________________________________                                        IV       2.7          61      7     35     2                                  V        0.6          62 ± 5                                                                             10 ± 2                                                                           .sup. 22 ± 6.sup.c                                                                6                                  VI       1.4          61       8 ± 3                                                                           12 ± 3                                                                            3                                  VII      1.8          68      8     19     1                                  VIII     10.3/21.9    43/55   3,4   6/36   2                                  IX       6.5 ± 1.8 49 ± 4                                                                              3 ± 1                                                                            8 ± 3                                                                            3                                  X        0.7          49            21     2                                  XI       0.2          81/71         >60                                       XXXV      0.08        95      >60   >60    1                                  Propanolol                                                                             0.2          67 ± 6                                                                             >60   >60    2                                  ______________________________________                                         .sup.a Percent inhibition of heart rate response to isoproterenol             .sup.b Number of experiments                                                  .sup.c 2/6 experiments did not recover to 80% within 60 min              

ENZYMATIC HYDROLYSIS OF BETA BLOCKERS BY DOG BLOOD, LIVER HOMOGENATE ANDAQUEOUS HUMOR Chemicals

Acetonitrile was "HPLC" grade. Distilled water was used to dissolve thecompounds and 0.01N HCl was used to dissolve compounds requiring anacidic pH for dissolution.

Enzyme Source

Fresh aqueous humor was collected from eyes of dogs using a 23-gaugeneedle while fresh dog blood was collected into heparinized Vacutainertubes. Fresh liver was homogenized in 0.9% NaCl using a Potter-ElvehjemTeflon pestle and glass homogenizer making a 25% (W/V) homogenate.

Incubation Condition

A 0.5 ml aliquot of dog aqueous humor, blood or liver homogenate wasincubated with 12.5 μg (0.5 ml) of beta blocker in a Dubnoff shakingmetabolic incubator at 37° C. for 60 and 120 min. Denatured tissuecontrols were prepared by adding 2.0 ml of acetonitrile into 0.5 ml ofaqueous humor, blood or liver homogenate to destroy esterase activitiesprior to addition of the beta blockers. These controls were thenincubated at 37° C. for 120 min. After 60 and 120 min, the incubationswere terminated by addition of 2 ml of acetonitrile and immediatelymixed by a Vortex® to stop esterase activities.

Sample Processing and Data Analyses

All samples were centrifuged at 4000 RPM for 10 min to sedimentdenatured proteins. The resultant supernatants were transferred to WISP®vials and analyzed using an HPLC assay developed for beta blockers. Thehydrolysis of beta blockers by aqueous humor, blood and liver homogenatewas determined by disappearance of the compounds. The extent ofenzymatic hydrolysis by each tissue was determined by comparing theamount of each compound (absolute peak area) recovered at each timepoint to the amount of each compound (absolute peak area) in denaturedtissue control and aqueous control samples. The results of theseexperiments are shown in Tabe III.

HALF-LIVES OF BETA BLOCKERS IN DOG WHOLE BLOOD AND DOG LIVER HOMOGENATE

These examples describe experiments which demonstrate the disappearanceof the compounds of the present invention in vitro in human whole blood,dog whole blood and dog liver homogenate. The rate of disappearance of acompound is expressed as the half-life (T1/2), which is the time periodin which one half of the initial amount of compound tested disappears.In each experiment, 1 ml of a solution containing 50 μg of the testcompound was added to 1 ml of whole blood or 1 ml of a 33% (w/v) liverhomogenate. The samples were incubated in a Dubnoff shaking metabolicincubator for 2.5, 5.0, 10.0, 20.0, 30.0 and 60.0 minutes at 37° C. Atthe designated time periods, the test mixtures were removed from theincubator and transferred to a 0° C. ice bath. Acetonitrile (2 ml) wasimmediately added and the mixtures were mixed to stop enzymatichydrolysis. Zero time samples were prepared by adding 2 ml ofacetonitrile to denature the proteins prior to addition of the testcompounds. After centrifugation to sediment denatured proteins, 2 ml ofthe supernatant was removed and analyzed by high pressure liquidchromatography, using a mobile phase of 60% acetonitrile/40% 0.05 msodium phosphate buffer (pH 6.6), a U.V. detector and Waters u BondapakPhenyl column. The half life of each test compound was determinedgraphically by plotting the decrease in concentrations as a function oftime. The results of the experiments are shown in Table III.

The present invention is further illustrated by the following exampleswhich are not intended to be limiting.

                                      TABLE III                                   __________________________________________________________________________    STABILITY IN DOG BLOOD, LIVER HOMOGENATE AND AQUEOUS HUMOR                    COMPOUND                DOG LIVER       DOG AQUEOUS                           OF      DOG BLOOD       HOMOGENATE      HUMOR                                 EXAMPLE % 1 HR.sup.a                                                                       % 2 HR.sup.a                                                                       T 1/2 min.sup.b                                                                     % 1 HR.sup.a                                                                       % 2 HR.sup.a                                                                       T 1/2 min.sup.b                                                                     % 1 HR.sup.a                                                                       % 2 HR.sup.a                                                                       T 1/2 min.sup.c             __________________________________________________________________________    VII     0    0    6     0    0    25    69   46   120                         V       12   8    20    0    0    3.5   75   49   120                         IV      0    0    7.5   39   23   --    87   52   120                         VIII    0    0    15    0    0    --    --   --   --                          II      0    0    15    0    0    --    58   32   60-120                      IX      0    0    8     0    0     1     0    0    0                          X       0    0    15    0    0    2.5    0    0    0                          __________________________________________________________________________     .sup.a Percent drug remaining determined by procedure C.                      .sup.b Halflife determined by procedure D.                                     .sup.c Approximate value determined by procedure C.                     

EXAMPLE I

This example describes the synthesis of a compound of the followingformula via Scheme III: ##STR21##

3-[(2-Isopropylcarbonylamino)ethylamino]1,2-propanediol

To 39 g (0.3 mol) of 2-(isopropylcarbonylamino)ethylamine in 150 ml ofisopropyl alcohol was added 22.2 g (0.3 mol) of glycidol. The reactionmixture was stirred at 25° C. for 24 hours and evaporated in vacuo. Theresidual oil was chromatographed (silica gel/ethanol) to give 18.6 g(30%) of product. This compound was identified by NMR and IRspectroscopy.

3-[N-(4-Methoxybenzyloxycarbonyl)-N-[(2-isopropylcarbonylamino)-ethyl]amino-1,2-propanediol

A mixture of 18.6 g (91 mmol) of the3-[2-(isopropylcarbonylamino)ethylamino]-1,2-propandiol, 20 g (97 mmol)of p-methoxybenzyloxycarbonyl azide and 24 g (280 mmol) of sodiumbicarbonate in 66 ml of dioxane and 33 mL of water was stirred at roomtemperature for 3 days.

The reaction mixture was filtered and the filtrate was evaporated todryness. The residue was chromatographed, silica gel/10% ethanol inchloroform to give 16 g (47.6%) of product. The compound was identifiedby NMR and IR spectroscopy.

2-Hydroxy-3-[N-[4-methoxybenzyloxycarbonyl]-N-[(2-isopropylcarbonylamino)ethyl]]aminopropyl2-Fluorobenzoate

To a mixture containing 8 g (2.2 mmol) of the diol from the previousexperiment in 50 ml of methylene chloride-pyridine (1:1) was added 3.5 g(2.2 mmol) of o-fluorobenzoyl chloride at 25° C. The reaction mixturewas stirred at 25° C. for 2.5 hours and evaporated to dryness in vacuoat 60° C. The residue was partitioned between water and methylenechloride. The methylene chloride layer was washed with 5% sodiumbicarbonate aqueous solution and evaporated to dryness. The product waspurified by chromatography; silica gel/10% ethanol in chloroform. Theyield was 75% and the compound was identified by NMR and IRspectroscopy.

3-[2-(Isopropylcarbonylamino)]ethyl]amino-2-hydroxypropyl2-Fluorobenzoate Hydrochloride

Hydrogen chloride gas was passed for 5 minutes into a mixture of 8 g ofthe ester obtained from the previous experiment in 150 ml of methylenechloride-ethanol (99:1). The reaction mixture was stirred at 25° C. for3 hours and the precipitate was filtered and recrystallized inisopropanol to give 3.3 g (56%) of product; m.p. 162.5°-163° C. The NMRand IR spectra were consistent with the assigned structure and theelemental analysis was consistent with the empirical formula C₁₆ H₂₄ N₂O₄ FCl.

EXAMPLE II

This example describes the synthesis of a compound of the followingformula via Method I: ##STR22##

3-[1,1-Dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate Hydrochloride

A mixture containing 37 g (0.5 mol) of glycidol, 500 ml of anhydrousethyl ether, 500 ml of pyridine and 80 g (0.5 mol) of o-fluorobenzoylchloride was stirred at 0° C. for 1 hour and 25° C. for 2 hours. Themixture was filtered and the ethanol filtrate was washed with 100 ml of5% hydrochloric acid. Evaporation of the ethyl ether gave an oil whichwas distilled to give 69.5 g (71%) of the product, 2,3-epoxypropyl2-fluorobenzoate, which had a boiling point of 115° C./0.5 mmHg. The NMRand IR spectra were consistent with the assigned structure.

To 8.5 g (0.043 mol) of 2,3-epoxypropyl 2-fluorobenzoate in 100 ml ofdimethylformamide was added 8.74 g (0.043 mol) of1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. The reactionmixture was stirred at 25° C. for 4 hours and the dimethylformamide wasevaporated in vacuo at 60° C. The product was purified by columnchromatography; silica gel/ethyl ether-ethanol (4:1) to give a colorlessoil which was dissolved in ether and acidified with etheral hydrochloricacid. The precipitate was filtered and recrystallized inisopropanol-ethyl ether to give 4.1 g (24%) of product; melting point58.5°-59.5° C. The NMR and IR spectra were consistent with the assignedstructure and elemental analysis was consistent with the empiricalformula C₁₉ H₂₉ N₃ O₅ FCl.

EXAMPLE III

This example describes the synthesis of a compound of the followingformula: ##STR23##

3-[1-methyl-2-(methylcarbonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate

The procedure of Example II was repeated in all essential details toproduce the above compound, except that an equivalent amount of1-methyl-2-(methylcarbonylamino)ethylamine was substituted for the1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. The product, whichwas recovered as a semisolid, had a melting point of 30° C. It wasidentified by NMR and IR spectroscopy and elemental analysis.

EXAMPLE IV

This example describes the synthesis of a compound of the followingformula: ##STR24##

3-[1,1-Dimethyl-2-(methylcarbonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of1,1-dimethyl-2-(methylcarbonylamino)ethylamine was substituted for the1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. The product, whichwas recovered as an oil, was identified by NMR and IR spectroscopy andelemental analysis.

EXAMPLE V

This example describes the synthesis of a compound of the followingformula: ##STR25##

3-[1,1-Dimethyl-2-(isopropylcarbonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate Oxalate Monohydrate

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of1,1-dimethyl-2-isopropylcarbonylaminoethylamine was substituted for the1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. The product, whichwas crystallized from isopropanol, had a melting point of 134.5°-137.5°C. and was identified by NMR and IR spectroscopy and elemental analysis.

EXAMPLE VI

This example describes the synthesis of a compound of the followingformula: ##STR26##

3-[1,1-Dimethyl-2-(cyclohexylcarbonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate Oxalate

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of1,1-dimethyl-2-cyclohexylcarbonylaminoethylamine was substituted for the1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. The product, whichwas crystallized from ethyl acetate-propanol, had a melting point of187°-188° C. and was identified by NMR and IR spectroscopy and elementalanalysis.

EXAMPLE VII

This example describes the synthesis of a compound of the followingformula: ##STR27##

3-[1,1-Dimethyl-2-(benzylcarbonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate Hydrochloride

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of1,1-dimethyl-2-benzylcarbonylaminoethylamine was substituted for the1,1-dimethyl-2-(morpholinocarbonylamino)ethylamine. The product, whichwas crystallized from isopropanol, had a melting point of 145.5°-146.5°C. and was identified by NMR and IR spectroscopy and elemental analysis.

EXAMPLE VIII

This example describes the synthesis of a compound of the followingformula: ##STR28##

3-[1,1-Dimethyl-2-(phenylsulfonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate Oxalate

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of1,1-dimethyl-2(phenylsulfonylamino)ethylamine was substituted for the1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. The product, whichwas crystallized from isopropanol, had a melting point of 152.4°-153° C.and was identified by NMR and IR spectroscopy and elemental analysis.

EXAMPLE IX

This example describes the synthesis of a compound of the followingformula: ##STR29##

3-[1,1-Dimethyl-2-(ethoxycarbonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate Hydrochloride

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of1,1-dimethyl-2-ethoxycarbonylaminoethylamine was substituted for the1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. The product, whichwas crystallized from ethyl acetate, had a melting point of 137° C. andwas identified by NMR and IR spectroscopy and elemental analysis.

EXAMPLE X

This example describes the synthesis of a compound of the followingformula ##STR30##

3-[1,1-Dimethyl-2-(aminocarbonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of1,1-dimethyl-2-(aminocarbonylamino)ethylamine was substituted for the1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. The product whichwas recrystallized from water, had a melting point of 58°-62° C. and wasidentified by NMR and IR spectroscopy and elemental analysis.

EXAMPLE XI

This example describes the synthesis of a compound of the followingformula: ##STR31##

3-[1,1-Dimethyl-2-(methylaminocarbonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate Hemioxalate

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of1,1-dimethyl-2-(methylaminocarbonylamino)ethylamine was substituted forthe 1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. The product,which was crystallized from isopropanol, had a melting point of 149.5°C. and was identified by NMR and IR spectroscopy and elemental analysis.

EXAMPLE XII

This example describes the synthesis of a compound of the followingformula: ##STR32##

3-[1,1-Dimethyl-2-(phenylaminocarbonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of1,1-dimethyl-2-(phenylaminocarbonylamino)ethylamine was substituted forthe 1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. The product,which was recovered as an oil, was identified by NMR and IR spectroscopyand elemental analysis.

EXAMPLE XIII

This example describes the synthesis of a compound of the followingformula: ##STR33##

3-[2-(Benzylcarbonylamino)ethyl]amino-2-hydroxypropyl 2-FluorobenzoateHydrochloride

The procedure of Example I was repeated in all essential details toproduce the above compound except that an equivalent amount of2-(benzylcarbonylamino)ethylamine was substituted for the2-(isopropylcarbonylamino)ethylamine. The product, which wascrystallized from isopropanol, had a melting point of 140.5° C. and wasidentified by NMR and IR spectroscopy and elemental analysis.

EXAMPLE XIV

This example describes the synthesis of an intermediate amine of thefollowing formula:

    H.sub.2 NC(CH.sub.3).sub.2 CH.sub.2 NHCOCH.sub.3

1,1-Dimethyl-2-(methylcarbonylamino)ethylamine

A mixture of 26.4 g (0.3 mol) of ethyl acetate and 79.2 g (0.9 mol) of1,2-diamino-2-methylpropane was heated at 100° C. in a pressure bomb for36 hours. The reaction mixture was evaporated in vacuo and distilled togive 22.4 g (57.4%) of product; boiling point 100° C./0.1 mmHg. Thisproduct was identified by NMR and IR spectroscopy.

EXAMPLE XV

This example describes the synthesis of an intermediate amine of thefollowing formula:

    H.sub.2 NCH.sub.2 CH.sub.2 NHCOCH(CH.sub.3).sub.2

2-(Isopropylcarbonylamino)ethylamine

The procedure of Example XIV was repeated in all essential details toproduce the above compound except that equivalent amounts of ethylenediamine and ethyl 2-methylpropionate were substituted for the1,2-diamino-2-methylpropane and ethyl acetate, respectively. Theproduct, which was recovered as an oil, was identified by NMR and IRspectroscopy and elemental analysis.

EXAMPLE XVI

This example describes the synthesis of an intermediate amine of thefollowing formula: ##STR34##

2-(Benzylcarbonylamino)ethylamine

The procedure of Example XIV was repeated in all essential details toproduce the above compound except that equivalent amounts of ethylenediamine and ethyl phenylacetate were substituted for the1,2-diamino-2-methylpropane and ethyl acetate, respectively. Theproduct, which had a melting point of 37°-38° C., was identified by NMRand IR spectroscopy.

EXAMPLE XVII

This example describes the synthesis of an intermediate amine of thefollowing formula:

    H.sub.2 NCH(CH.sub.3)CH.sub.2 NHCOCH.sub.3

1-Methyl-2-(methylcarbonylamino)ethylamine

The procedure of Example XIV was repeated in all essential details toproduce the above compound except that an equivalent amount of1,2-diaminopropane was substituted for 1,2-diamino-2-methylpropane. Theproduct, which had a boiling point of 90°-95° C. at 0.1 mmHg, wasidentified by NMR and IR spectroscopy.

EXAMPLE XVIII

This example describes the synthesis of an intermediate amine of thefollowing formula:

    H.sub.2 NCH.sub.2 CH.sub.2 NHCOCH.sub.3

2-(Methylcarbonylamino)ethylamine

The procedure of Example XIV was repeated in all essential details toproduce the above compound except that an equivalent amount of ethylenediamine was substituted for 1,2-diamino-2-methylpropane. The product,which had a melting point of 51°-52° C., was identified by NMR and IRspectroscopy.

EXAMPLE IXX

This example describes the synthesis of an intermediate amine of thefollowing formula:

    H.sub.2 NC(CH.sub.3).sub.2 CH.sub.2 NHCOCH(CH.sub.3).sub.2

1,1-Dimethyl-2-(isopropylcarbonylamino)ethylamine

The procedure of Example XIV was repeated in all essential details toproduce the above compound except that an equivalent amount of ethyl2-methylpropionate was substituted for ethyl acetate. The product, whichhad a boiling point of 110° C. at 0.1 mmHg, was identified by NMR and IRspectroscopy.

EXAMPLE XX

This example describes the synthesis of an intermediate amine of thefollowing formula: ##STR35##

1,1-Dimethyl-2-(cyclohexylcarbonylamino)ethylamine

The procedure of Example XIV was repeated in all essential details toproduce the above compound except that an equivalent amount of ethylcyclohexylcarboxylate was substituted for ethyl acetate. The product,which had a boiling point of 100°-110° C. at 0.1 mmHg, was identified byNMR and IR spectroscopy.

EXAMPLE XXI

This example describes the synthesis of an intermediate amine of thefollowing formula: ##STR36##

1,1-Dimethyl-2-(benzylcarbonylamino)ethylamine

The procedure of Example XIV was repeated in all essential details toproduce the above compound except that an equivalent amount of ethylphenylacetate was substituted for ethyl acetate. The product, which hada melting point of 46.5° C., was identified by NMR and IR spectroscopy.

EXAMPLE XXII

This example describes the synthesis of an amine of the followingformula:

    H.sub.2 NC(CH.sub.3).sub.2 CH.sub.2 NHCOOC.sub.2 H.sub.5

1,1-Dimethyl-2-(ethoxycarbonyl)aminoethylamine

To a mixture of 88.2 g (1 mol) of 1,2-diamino-2-methylpropane, 50 ml oftriethylamine and 500 ml of diethyl ether was added dropwise to asolution of 27.1 g (0.25 mol) of ethyl chloroformate in 100 mL of ether.The reaction mixture was stirred for 16 hours at 25° C. and filtered.Evaporation of the filtrate to dryness gave 38 g (95%) of product whichwas identified by NMR and IR spectroscopy.

EXAMPLE XXIII

This example describes the synthesis of an amine of the followingformula:

    H.sub.2 NC(CH.sub.3).sub.2 CH.sub.2 NHCONHCH.sub.3

1,1-Dimethyl-2-(methylaminocarbonylamino)ethylamine

A reaction mixture of 5.7 g (1 mol) of methyl isocyanate and 20 ml ofpyridine was stirred at 0° C. for 5 minutes and slowly added into asolution of 20 g (0.23 mol) 1,2-diamino-2-methylpropane in 30 ml ofpyridine. The reaction mixture was warmed to 20° C. and stirred for 1hour. Evaporation of the solvent in vacuo gave 11.6 g (90%) of productwhich was identified by NMR and IR spectroscopy.

EXAMPLE XXIV

This example describes the synthesis of an amine of the followingformula:

    H.sub.2 NC(CH.sub.3).sub.2 CH.sub.2 NHCONH.sub.2

1,1-Dimethyl-2-(aminocarbonylamino)ethylamine

The procedure of Example XXIII was repeated in all essential details toproduce the above compound except that an equivalent amount of cyanicacid was substituted for methyl isocyanate. The product was recovered asa semi-solid.

Alternatively, the urea of this example was prepared as follows: Amixture of 26.5 g (0.3 mol) of 1,2-diamino-2-methylpropane, and 18 g(0.3 mol) of urea in 150 ml of water was refluxed for 4 hours. Themixture was evaporated in vacuo. The residue was dissolved inchloroform, filtered and evaporated to form a solid which wasrecrystallized in ethyl acetate to give 15 g of product (38%), m.p.87°-90° C. The NMR and IR spectra were consistent with the assignedstructre.

EXAMPLE XXV

This example describes the synthesis of an amine of the followingformula: ##STR37##

1,1-Dimethyl-2-(1-morpholinocarbonylamino)ethylamine

To 16.2 g (0.1) of N,N'-carbonyldiimidazole in 100 ml of chloroform wasadded 8.7 g (0.1 mol) of morpholine. The reaction mixture was stirredfor 30 minutes at 25° C. and slowly added to a solution of1,2-diamino-2-methylpropane in 100 ml of chloroform. After stirring for30 minutes, the reaction was evaporated to dryness and the product waschromatographed; silica gel/ethanol-ethyl ether (1:1) to give 8.74 g(43%) of product. The NMR and IR spectra were consistent with theassigned structure.

EXAMPLE XXVI

This example describes the synthesis of an amine of the followingformula: ##STR38##

1,1-Dimethyl-2-(phenylaminocarbonylamino)ethylamine

The procedure of Example XXV was repeated in all essential details toproduce the above compound except that an equivalent amount of anilinewas substituted for morpholine. The product, which had a melting pointof 130.5°-131°, was identified by NMR and IR spectroscopy.

EXAMPLE XXVII

This example describes the synthesis of an amine of the followingformula:

    H.sub.2 NCH.sub.2 CH.sub.2 NHCONHCH.sub.3.HCl

2-(Methylaminocarbonylamino)ethylamine

3.23 g (0.057 mol) of methyl isocynate was added dropwise to a stirringsuspension of 5 g (0.057 mol) of acetylethylenediamine in 100 ml ofmethylene chloride at 10° C. After the addition of methyl isocyanate wascompleted, 100 ml of anhydrous ether was added to the reaction mixtureand stirring was continued for another 30 minutes. A solid having amelting point of 143°-144° C. was collected by filtration. It wasdissolved in 50 ml of 15% hydrochloric acid and heated to 80° C. for 4hours. Removal of the aqueous acid under reduced pressure afforded theproduct as an oil which was identified by its NMR and IR spectra.

EXAMPLE XVIII

This example describes the synthesis of an amine of the followingformula: ##STR39##

2-(Phenylaminocarbonylamino)ethylamine

The procedure of Example XXVII was repeated in all essential details toproduce the above compound except that an equivalent amount of phenylisocyanate was substituted for methyl isocyanate. The product had amelting point of 190.4° C.

EXAMPLE XXIX

This example describes the synthesis of an amine of the followingformula: ##STR40##

1,1-Dimethyl-2-(phenylsulfonylamino)ethylamine

To a mixture of 14.97 g (0.169 mol) of 1,2-diamino-2-methylpropane in300 ml of chloroform and 80 ml pyridine was added 10 g (0.057 mol) ofbenzenesulfonyl chloride at 0° C. The reaction mixture was stirred at 0°C. for 30 minutes and allowed to reach room temperature. The mixture wasevaporated to dryness in vacuo and the residue was partitioned betweenwater and chloroform. Evaporation of the chloroform gave 10.3 g (79%) ofsemisolid. The product was identified by NMR and IR spectroscopy andelemental analysis.

EXAMPLE XXX

This example describes the synthesis of an amine of the followingformula: ##STR41##

2-(p-Methylphenylsulfonylamino)ethylamine

The procedure of Example XXIX is repeated in all essential details togive the above product except that equivalent amounts ofp-toluenesulfonyl chloride and ethylenediamine are substituted forbenzenesulfonyl chloride and 1,2-diamino-2-methylpropane, respectively.

EXAMPLE XXXI

This example describes the synthesis of a compound of the followingformula: ##STR42##

3-[1,1-Dimethyl-2-[(2-methoxy)ethoxycarbonylamino]]ethylamino-2-hydroxypropyl2-Fluorobenzoate Oxalate

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of1,1-dimethyl-2-[(2-methoxy)ethoxycarbonylamino)ethylamine wassubstituted for the1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. The product, whichwas crystallized from ethyl acetate, had a melting point of 94°-96° C.and was identified by NMR and IR spectroscopy and elemental analysis.

EXAMPLE XXXII

This example describes the synthesis of a compound of the followingformula: ##STR43##

3-[1,1-Dimethyl-2-(dimethylaminosulfonylamino)]ethylamino-2-hydroxypropyl2-Fluorobenzoate Oxalate

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of1,1-dimethyl-2-(dimethylaminosulfonylamino)ethylamine was substitutedfor the 1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine. Theproduct, which was crystallized from acetone-ethylamine, had a meltingpoint of 124°-125° C. and was identified by NMR and IR spectroscopy andelemental analysis.

EXAMPLE XXXIII

This example describes the synthesis of a compound of the followingformula: ##STR44##

3-[1,1-Dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropylBenzoate Oxalate Hemihydrate

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount of benzoylchloride was substituted for o-fluorobenzoyl chloride. The product,which was recrystallized from ethyl acetate, had a melting point of141°-143° C. and was identified by NMR and IR spectroscopy and elementalanalysis.

EXAMPLE XXXIV

This example describes the synthesis of a compound of the followingformula: ##STR45##

3-[1,1-Dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl2-Chlorobenzoate Oxalate

The procedure of Example II was repeated in all essential details toproduce the above compound except that an equivalent amount ofo-chlorobenzoyl chloride was substituted for o-fluorobenzoyl chloride.The product, which was recrystallized from isopropanol- ether, had amelting point of 117°-119° C. and was identified by NMR and IRspectroscopy and elemental analysis.

EXAMPLE XXXV

This sample describes the synthesis of a compound of the followingformula: ##STR46##

Ethyl 3,4-Dihydroxybenzoate

A mixture which contained 43 g (0.28 mole) of 3,4-dihydroxybenzoic acid,300 ml of ethanol and 0.5 ml of concentrated H₂ SO₄ was refluxed for 48hours. Water was trapped with 3A molecular sieves. The reaction mixturewas evaporated to dryness in vacuo, and partitioned between ether and 5%NaHCO₃ solution. The ether layer was evaporated to give 39 g (69%) ofsolid; m.p. 128°-130° C. The NMR and IR spectra were consistent with theassigned structure.

3,4-Dibenzyloxybenzoic Acid

To 60 g (0.33 mole) of ethyl 3,4-dihydroxybenzoate in 50 ml of methylethyl ketone was added 105.5 g (0.76 mole) of K₂ CO₃ and 168.8 g (0.76mole) of benzyl bromide. The mixture was refluxed for 16 hours andfiltered. Evaporation of the filtration gave an oil. This oil was mixedwith 40 g of KOH, 350 ml of water and 350 ml of methanol and refluxedfor 2.5 hours. The methanol was evaporated and the reaction mixture wasacidified with concentrated HCl. The precipitate was filtered to give101 g (92%) of the desired product; m.p. 184°-185° C. The NMR and IRspectra were consistent with the assigned structure.

3-[1,1-Dimethyl-2-(1-morpholinocarbonylamino)ethyl]amino-2-hydroxypropyl3,4-Dibenzyloxybenzoate Oxalate Monohydrate

To 5 g (15 mmol) of the 3,4-dibenzyloxybenzoic acid in 30 ml of toluenewas added 20 g (110 mmol) of thionyl chloride. The reaction mixture wasrefluxed for 2 hours and evaporated in vacuo to a solid. The solid wasdissolved in 20 ml of toluene and added dropwise into a solution of 4.1g (15 mmol)3-[1,1-dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-1,2-propandiolin 10 ml of pyridine and 20 ml of toluene. The reaction mixture wasstirred for 1 hour at 25° C. and evaporated to dryness. The residue wasdissolved in acetone and basified with K₂ CO₃. The acetone solution wasfiltered, evaporated to dryness and the residue was mixed with anequivalent amount of oxalic acid in isopropanol-ether to give 1.5 g(14.3%) of crystalline product, m.p. 162°-163° C. The NMR and IR spectrawere consistent with the assigned structure and the elemental analysiswas consistent with the empirical formula C₃₅ H₄₅ O₁₂ N₃.

3-[2-[1,1-Dimethyl-2-(1-morpholinocarbonylamino)]ethyl]amino-2-hydroxypropyl3,4-Dihydroxybenzoate Oxalate Monohydrate

A mixture of 1 g of the dibenzyloxybenzoate from the previousexperiment, 100 mg of 10% Pd/C and 75 ml of methanol was agitated for 30minutes under 50 psi of hydrogen. The catalyst was filtered and thefiltrate was evaporated to dryness. The residue was crystallized inethanol-ether to give 0.4 g (54%) of product; m.p. 145°-147° C. Thecompound was identified by NMR, IR and elemental analysis.

EXAMPLE XXXVI

This example describes the synthesis of a compound of the followingformula: ##STR47##

3-[1,1-Dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl4-Hydroxbenzoate Oxalate

The procedure of Example XXXV was repeated in all essential details toproduce the above compound except that an equivalent amount of4-hydroxybenzoic acid was substituted for the 3,4-dihydroxybenzoic acid.The product, which was crystallized from isopropanol-ethylacetate-ether, had a melting point of 176°-177° C. and was identified byNMR and IR spectroscopy and elemental analysis.

EXAMPLE XXXVII

This example describes the synthesis of a compound of the followingformula: ##STR48##

3-[1,1-Dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl2-Methyl-4-hydroxybenzoate Oxalate

The procedure of Example XXXV was repeated in all essential details toproduce the above compound except that an equivalent amount of2-methyl-4-hydroxybenzoic acid was substituted for the3,4-dihydroxybenzoic acid. The product, which was recrystallized fromisopropanol-ether, had a melting point of 160°-161° C. and wasidentified by NMR and IR spectroscopy and elemental analysis.

EXAMPLE XXXVIII

This example describes the synthesis of a compound of the followingformula: ##STR49##

3-[1,1-Dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl3,5-Dihydroxybenzoate Oxalate Hemihydrate

The procedure of Example XXXV was repeated in all essential details toproduce the above compound except that an equivalent amount of3,5-dihydroxybenzoic acid was substituted for the 3,4-dihydroxybenzoicacid. The product, which was precipitated from isopropanol with ether,was hygroscopic and was identified by NMR and IR spectrocopy andelemental analysis.

EXAMPLE XXXIX

This example describes the synthesis of an amine of the the followingformula: ##STR50##

1,1-Dimethyl-2-(methoxyethoxycarbonylamino)ethylamine

To 10 g (62 mmol) of N,N'-carbonyldiimidazole in 100 ml of methylenechloride was added 4.7 g (62 mmol) of 2-methoxyethanol. The reactionmixture was timed at 25° C. for one hour and 10.9 g (124 mmol) of1,2-diamino-2-methylpropane was added. Stirring was continued for 18hours and the reaction was evaporated to dryness. The product waschromatographed on silica gel/EtOH:EtOAc (1:1) to give 9.5 g (80.5%) ofproduct. The NMR and IR were consistent with the assigned structure.

EXAMPLE XXXX

This example describes the synthesis of an amine of the followingformula:

    H.sub.2 NC(CH.sub.3).sub.2 CH.sub.2 NHSO.sub.2 N(CH.sub.3).sub.2

1,1-Dimethyl-2-[(dimethylamino)sulfonylamino]ethylamine

A mixture of 30.7 g (0.35 mol) of 1,2-diamino-2-methylpropane, 150 ml ofether and 50 ml of triethylamine was cooled to 0° C. and 20 g (0.14 mol)of dimethylsulfamoyl chloride was added slowly. The reaction mixture wasstirred for 30 minutes and evaporated to dryness. The residue was mixedwith water, basified with K₂ CO₃ and evaporated to dryness. Acetone wasadded and the mixture was filtered. Evaporation of the filtrate gave asolid which was recrystalized from toluene to give 16.5 g (60.3%) ofproduct, mp 77°-78° C. The NMR and IR were consistent with the assignedstructure.

EXAMPLE XXXXI

This example describes the synthesis of a compound of the followingformula:

    H.sub.2 NCH.sub.2 CH.sub.2 NHSO.sub.2 N(CH.sub.3).sub.2.HCl

2-[(Dimethyaminosulfonylamino]ethylamine Hydrochloride

A solution of 14.3 g (0.1 mole) of dimethylsulfamoyl chloride in 50 mlof methylene chloride was added dropwise to a rapidly stirred solutionof 10.2 g (0.1 mole) of acetylethylene diamine and 10.1 g (0.1 mole) oftriethylamine in 150 ml of methylene chloride at 25° C. After theaddition was completed, the solution was stirred for 30 min and thenwashed in a separatory funnel with two 100 ml portions of water. Theorganic phase was separated, and dried over MgSO₄, and then concentratedunder reduced pressure to affordN-[2[(dimethylamino)sulfonylamino]ethyl]acetamide as an oil. TheN-acetyl group was then removed by treatment of the oil with 100 ml of15% HCl at 80° C. for 6 h. This solution was concentrated under reducedpressure to provide 12.6 g (73%) of product as an oil. The NMR spectrumwas consistent with the assigned structure.

EXAMPLE XXXXII

This example describes the synthesis of a compound of the followingformula: ##STR51##

3-[1,1-Dimethyl-2-(morpholinocarbonylamino)ethylamino]-1,2-propandiol

A mixture of 20 g (0.1 mol) of1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamine, 7.4 g (0.1 mol) ofglycidol and 50 ml of tetrahydrofuran was refluxed for 18 hours. Thesolvent was evaporated in vacuo to give the product which was identifiedby NMR and IR.

EXAMPLE XXXXIII

The procedure of Example II is repeated in all essential details toproduce the compounds identified in the following table, except that anequivalent amount of the reactant listed in the first column issubstituted for o-fluorobenzoyl chloride.

    ______________________________________                                         ##STR52##                                                                     ##STR53##            Ar                                                      ______________________________________                                        1-naphthoyl chloride 1-naphthyl                                               2-naphthoyl chloride 2-naphthyl                                               2-methylbenzoyl chloride                                                                           2-methylphenyl                                           3-fluorobenzoyl chloride                                                                           3-fluorophenyl                                           4-fluorobenzoyl chloride                                                                           4-fluorophenyl                                           3-nitrobenzoyl chloride                                                                            3-nitrophenyl                                            4-nitrobenzoyl chloride                                                                            4-nitrophenyl                                            4-methoxybenzoyl chloride                                                                          4-methoxyphenyl                                          4-cyanobenzoyl chloride                                                                            4-cyanophenyl                                            2-allyloxybenzoyl chloride                                                                         3-allyloxyphenyl                                         3-allyloxybenzoyl chloride                                                                         3-allyloxyphenyl                                         2-n-propyloxybenzoyl chloride                                                                      2-n-propyloxyphenyl                                      4-formylbenzoyl chloride                                                                           4-formylphenyl                                           4-benzyloxybenzoyl chloride                                                                        4-benzyloxyphenyl                                        3,4-benzyloxybenzoyl chloride                                                                      3,4-benzyloxylyphenyl                                    2-methylbenzoyl chloride                                                                           2-methylphenyl                                           3-nitrobenzoyl chloride                                                                            3-nitrophenyl                                            4-nitrobenzoyl chloride                                                                            4-nitrophenyl                                            2-methyl-4-nitrobenzoyl chloride                                                                   2-methyl-4-nitrophenyl                                   4-n-butyloxybenzoyl chloride                                                                       4-n-butyloxyphenyl                                       3,4,5-tribenzyloxybenzoyl                                                                          3,4,5-benzyloxyphenyl                                    chloride                                                                      ______________________________________                                    

EXAMPLE XXXXIV

This example describes the synthesis of a compound of the formula:##STR54##

3-[1,1-Dimethyl-2-(1-morpholinocarbonylamino)ethylamino]-2-hydroxypropyl4-Aminobenzoate

To 20 mg of 10% Pd-C in 30 ml of methanol is added 0.00125 moles ofmethanol is added 0.00125 mole of3-[1,1-dimethyl-2-(1-morpholinocarbonylamino)ethylamino]-2-hydroxypropyl4-nitrobenzoate prepared in Example XXXXIII. The reaction vessel is keptunder 30 psi of hydrogen and agitated for 1 hour. The catalyst isfiltered and the methanol evaporated to give the product.

What we claim is:
 1. A compound of the formula ##STR55## wherein Arrepresents a phenyl or naphthyl group which may be unsubstituted orsubstituted with lower alkyl from 1 to about 6 carbon atoms, alkenyl offrom 1 to about 6 carbon atoms, alkynyl of from 2 to about 10 carbonatoms, alkoxy wherein the alkyl group contains from 1 to about 6 carbonatoms, halogen, acetamido, amino, nitro, phenoxy, alkylamino of from 1to about 10 carbon atoms, hydroxy, hydroxyalkyl of from 1 to about 10carbon atoms, cyano, arylalkoxy wherein the alkyl group contains from 1to about 6 carbon atoms and the aryl group represents phenyl which maybe unsubstituted or substituted with lower alkyl from 1 to about 6carbon atoms, alkenyl of from 2 to about 6 carbon atoms, alkynyl of from2 to about 10 carbon atoms, alkoxy wherein the alkyl group contains from1 to about 6 carbon atoms, halogen, acetamido, amino, nitro, phenoxy,alkylamino of from 1 to about 10 carbon atoms, hydroxy, hydroxyalkyl offrom 1 to about 10 carbon atoms, cyano; W represents alkylene of from 1to about 10 carbon atoms; and B represents --NHCONR₁ R₃ or --NHSO₂ NR₁R₃ wherein R₁ and R₃ together with N form a morpholino ring; or apharmaceutically acceptable salt thereof.
 2. A compound according toclaim 1 of the formula ##STR56## wherein Ar represents phenyl ornaphthyl group which may be unsubstituted or substituted with alkyl offrom 1 to about 6 carbon atoms, alkenyl of from 2 to about 6 carbonatoms, alkynyl of from 2 to about 10 carbon atoms, alkoxy wherein thealkyl group contains from 1 to about 6 carbons atoms, halogen,acetamido, amino, nitro, alkylamino of from 1 to about 6 carbon atoms,hydroxy, hydroxyalkyl of from 1 to about 6 carbon atoms, cyano orarylalkoxy wherein the alkyl group contains from 1 to about 6 carbonatoms and the aryl group is substituted or unsubstituted phenyl; Wrepresents alkylene of from 1 to about 10 carbon atoms; and B represents--NHCONR₁ R₃ or --NHSO₂ NR₁ R₃ wherein R₁ and R₃ together with N form amorpholino ring; or a pharmaceutically acceptable salt thereof.
 3. Acompound according to claim 1 of the formula ##STR57## wherein Arrepresents phenyl which is unsubstituted or substituted with alkyl offrom 1 to about 6 carbon atoms, alkoxy wherein the alkyl group containsfrom 1 to about 4 carbon atoms, halogen, hydroxy, nitro, amino, phenoxy,or benzyloxy; W represents alkylene of from 1 to about 6 carbon atoms;and B represents --NHCONR₁ R₃ or --NHSO₂ NR₁ R₃ wherein R₁ and R₃together with N form a morpholino ring; or a pharmaceutically acceptablesalt thereof.
 4. A compound according to claim 1 of the formula##STR58## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, hydroxyalkyl of from 1 to about 6carbon atoms, nitro, amino, alkyl of from 1 to about 6 carbon atoms,phenoxy, benzyloxy, or alkoxy wherein the alkyl group contains from 1 toabout 4 carbon atoms; W represents alkylene of from 1 to about 6 carbonatoms; and B represents --NHCONR₁ R₃ or --NHSO₂ NR₁ R₃ wherein R₁ and R₃together with N form a morpholino ring; or a pharmaceutically acceptablesalt thereof.
 5. A compound according to claim 1 of the formula##STR59## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, hydroxyalkyl of from 1 to about 6carbon atoms, nitro, amino, benzyloxy, phenoxy, alkyl containing from 1to about 6 carbon atoms, or alkoxy wherein the alkyl group contains from1 to about 6 carbon atoms; W represents alkylene of from 1 to about 6carbon atoms; and Y is --CONR₁ R₃ or --SO₂ NR₁ R₃ wherein R₁ and R₃together with N form a morpholino ring; or a pharmaceutically acceptablesalt thereof.
 6. A compound according to claim 1 of the formula##STR60## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, nitro, amino, alkyl of from 1 toabout 4 carbon atoms, or benzyloxy; W represents alkylene of from 1 toabout 6 carbon atoms; and R₁ and R₃ together with N form a morpholinoring; or a pharmaceutically acceptable salt thereof.
 7. A compoundaccording to claim 1 of the formula ##STR61## wherein X₁, X₂ and X₃ maybe the same or different and represent hydrogen, halogen, hydroxy,nitro, amino, alkyl of from 1 to about 4 carbon atoms, or benzyloxy; Wrepresents alkylene of from 1 to about 6 carbon atoms; and R₁ and R₃ maytogether with N form a morpholino ring; or a pharmaceutically acceptablesalt thereof.
 8. A compound according to claim 1 which is3-[1,1-dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropylbenzoate.
 9. A compound according to claim 1 which is3-[1,1-dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl2-chlorobenzoate.
 10. A compound according to claim 1 which is3-[1,1-dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl3,4-dihydroxybenzoate.
 11. A compound according to claim 1 which is3-[1,1-dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl4-hydroxybenzoate.
 12. A compound according to claim 1 which is3-[1,1-dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl2-methyl-4-hydroxybenzoate.
 13. A compound according to claim 1 which is3-[1,1-dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl3,5-dihydroxybenzoate.
 14. A compound according to claim 1 which is3-[1,1-dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl2-fluorobenzoate.
 15. A compound according to claim 1 which is3-[1,1-dimethyl-2-(1-morpholinocarbonylamino)]ethylamino-2-hydroxypropyl2-fluorobenzoate hydrochloride.
 16. A method for the treatment ofcardiac disorders in a mammal comprising administering to such animal ashort-acting beta-blocking compound of the formula ##STR62## wherein Arrepresents a phenyl or naphthyl group which may be unsubstituted orsubstituted with lower alkyl of from 1 to about 10 carbon atoms, alkenylof from 2 to about 10 carbon atoms, alkynyl of from 2 to about 10 carbonatoms, alkoxy wherein the alkyl group contains from 1 to about 10 carbonatoms, halogen, acetamido, amino, nitro, alkylamino of from 1 to about10 carbon atoms, hydroxy, hydroxyalkyl of from 1 to about 10 carbonatoms, cyano, arylalkoxy wherein the alkyl group contains from 1 toabout 6 carbon atoms and the aryl group represents substituted orunsubstituted phenyl and groups of the formula ##STR63## wherein R₄ islower alkyl, aryl or aralkyl and A is a direct bond, alkylene of from 1to about 10 carbon atoms or alkenylene of from 2 to about 10 carbonatoms; W represents alkylene of from 1 to about 10 carbon atoms; and Brepresents --NHCONR₁ R₃ or --NHSO₂ NR₁ R₃ wherein R₁ and R₃ togetherwith N form a morpholino ring; or a pharmaceutically acceptable saltthereof.
 17. The method of claim 16 wherein the compound is of theformula ##STR64## wherein Ar represents a phenyl or naphthyl group whichmay be unsubstituted or substituted with alkyl of from 1 to about 6carbon atoms, alkenyl of from 2 to about 6 carbon atoms, alkynyl of from2 to about 10 carbon atoms, alkoxy wherein the alkyl group contains from1 to about 6 carbon atoms, halogen, acetamido, amino, nitro, alkylaminoof from 1 to about 6 carbon atoms, hydroxy, hydroxyalkyl of from 1 toabout 6 carbon atoms, cyano or arylalkoxy wherein the alkyl groupcontains from 1 to about 6 carbon atoms and the aryl group is phenyl;which may be unsubstituted or substituted with alkyl of from 1 to about6 carbon atoms, alkoxy wherein the alkyl group contains from 1 to about4 carbon atoms, halogen, hydroxy, nitro, amino, phenoxy, or benzyloxy; Wrepresents alkylene of from 1 to about 10 carbon atoms; and B represents--NHCONR₁ R₃ or --NHSO₂ NR₁ R₃ wherein R₁ and R₃ together with N form amorpholino ring; or a pharmaceutically acceptable salt thereof.
 18. Themethod of claim 16 wherein the compound is of the formula ##STR65##wherein Ar represents phenyl which is unsubstituted or substituted withalkyl of from 1 to about 6 carbon atoms, alkoxy wherein the alkyl groupcontains from 1 to about 4 carbon atoms, halogen, hydroxy, nitro, amino,phenoxy, or benzyloxy; W represents alkylene of from 1 to about 6 carbonatoms; and B represents --NHCONR₁ R₃ or --NHSO₂ NR₁ R₃ wherein R₁ and R₃together with N form a morpholino ring; or a pharmaceutically acceptablesalt thereof.
 19. The method of claim 16 wherein the compound is of theformula ##STR66## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, hydroxyalkyl of from 1 to about 6carbon atoms, nitro, amino, alkyl of from 1 to about 6 carbon atoms,phenoxy, benzyloxy, or alkoxy wherein the alkyl group contains from 1 toabout 4 carbon atoms; W represents alkylene of from 1 to about 6 carbonatoms; and B represents --NHCONR₁ R₃ or --NHSO₂ NR₁ R₃ wherein R₁ and R₃together with N form a morpholino ring; or a pharmaceutically acceptablesalt thereof.
 20. The method of claim 16 wherein the compound is of theformula ##STR67## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, hydroxyalkyl of from 1 to about 6carbon atoms, nitro, amino, benzyloxy, phenoxy, alkyl containing from 1to about 6 carbon atoms, or alkoxy wherein the alkyl group contains from1 to about 6 carbon atoms; W represents ethylene, 1-methylethylene, or1,1-dimethylethylene, and Y is --CONR₁ R₃ or --SO₂ NR₁ R₃ wherein R₁ andR₃ together with N form a morpholino ring; or a pharmaceuticallyacceptable salt thereof.
 21. The method of claim 16 wherein the compoundis of the formula ##STR68## wherein X₁, X₂ and X₃ may be the same ordifferent and represent hydrogen, halogen, hydroxy, nitro, amino, alkylof from 1 to about 4 carbon atoms, or benzyloxy; W represents alkyleneof from 1 to about 6 carbon atoms; and R₁ and R₃ together with N form amorpholino ring; or a pharmaceutically acceptable salt thereof.
 22. Amethod of treating glaucoma or lowering intraocular pressure in amammal, which comprises topically applying to the eye of said mammal anintraocular pressure-lowering effective amount of a compound of theformula ##STR69## wherein Ar represents a phenyl or naphthyl group whichmay be unsubstituted or substituted with lower alkyl of from 1 to about10 carbon atoms, alkenyl of from 2 to about 10 carbon atoms, alkynyl offrom 2 to about 10 carbon atoms, alkoxy wherein the alkyl group containsfrom 1 to about 10 carbon atoms, halogen, acetamido, amino, nitro,alkylamino, of from 1 to about 10 carbon atoms, hydroxy, hydroxyalkyl offrom 1 to about 10 carbon atoms, cyano, arylalkoxy wherein the alkylgroup contains from 1 to about 6 carbon atoms and the aryl grouprepresents substituted or unsubstituted phenyl; W represents alkylene offrom 1 to about 10 carbon atoms; and B represents --NHCONR₁ R₃ or--NHSO₂ NR₁ R₃ wherein R₁ and R₃ together with N form a morpholino ring;or a pharmaceutically acceptable salt thereof.
 23. The method of claim22 wherein the compound is of the formula ##STR70## wherein Arrepresents a phenyl or naphthyl group which may be unsubstituted orsubstituted with alkyl of from 1 to about 6 carbon atoms, alkenyl offrom 2 to about 6 carbon atoms, alkynyl of from 2 to about 10 carbonatoms, alkoxy wherein the alkyl group contains from 1 to about 6 carbonatoms, halogen, acetamido, amino, nitro, alkylamino of from 1 to about 6carbon atoms, hydroxy, hydroxyalkyl of from 1 to about 6 carbon atoms,cyano or arylalkoxy wherein the alkyl group contains from 1 to about 6carbon atoms and the aryl group is phenyl which may be unsubstituted orsubstituted with alkyl of from 1 to about 6 carbon atoms, alkoxy whereinthe alkyl group contains from 1 to about 4 carbon atoms, halogen,hydroxy, nitro, amino, phenoxy or benzyloxy; W represents alkylene offrom 1 to about 10 carbon atoms; and B represents --NHCONR₁ R₃ or--NHSO.sub. 2 NR₁ R₃ wherein R₁ and R₃ together with N form a morpholinoring; or a pharmaceutically acceptable salt thereof.
 24. The method ofclaim 22 wherein the compound is of the formula ##STR71## wherein Arrepresents phenyl which is unsubstituted or substituted with alkyl offrom 1 to about 6 carbon atoms, alkoxy wherein the alkyl group containsfrom 1 to about 4 carbon atoms, halogen, hydroxy, nitro, amino, phenoxy,or benzyloxy; W represents alkylene of from 1 to about 6 carbon atoms;and B represents --NHCONR₁ R₃ or --NHSO₂ NR₁ R₃ wherein R₁ and R₃together with N form a morpholino ring; or a pharmaceutically acceptablesalt thereof.
 25. The method of claim 22 wherein the compound is of theformula ##STR72## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, hydroxyalkyl of from 1 to about 6carbon atoms, nitro, amino, alkyl of from 1 to about 6 carbon atoms,phenoxy, benzyloxy, or alkoxy wherein the alkyl group contains from 1 toabout 4 carbon atoms; W represents alkylene of from 1 to about 6 carbonatoms; and B represents --NHCONR₁ R₃ or --NHSO₂ NR₁ R₃ wherein R₁ and R₃together with N form a morpholino ring; or a pharmaceutically acceptablesalt thereof.
 26. The method of claim 22 wherein the compound is of theformula ##STR73## wherein X₁, X₂ and X₃ may be the same or different andrepresent hydrogen, halogen, hydroxy, hydroxyalkyl of from 1 to about 6carbon atoms, nitro, amino, benzyloxy, phenoxy, alkyl containing from 1to about 6 carbon atoms, or alkoxy wherein the alkyl group contains from1 to about 6 carbon atoms; W represents ethylene, 1-methylethylene, or1,1-dimethylethylene, and Y is --CONR₁ R₃ or --SO₂ NR₁ R₃ wherein R₁ andR₃ together with N form a morpholino ring; or a pharmaceuticallyacceptable salt thereof.
 27. The method of claim 22 wherein the compoundis of the formula ##STR74## wherein X₁, X₂ and X₃ may be the same ordifferent and represent hydrogen, halogen, hydroxy, nitro, amino, alkylof from 1 to about 4 carbon atoms, or benzyloxy; W represents alkyleneof from 1 to about 6 carbon atoms; and R₁ and R₃ together with N form amorpholino ring; or a pharmaceutically acceptable salt thereof.